Artuela Çaku

Lipoprotein(a) Levels and the Risk of Myocardial Infarction Among 7 Ethnic Groups

Guillaume Paré, Artuela Çaku, Matthew McQueen et al. · Circulation · 2019 · 391 citations · Full text

Medicine, Cardiology, Clinical Epidemiology +16

Effect of lovastatin on behavior in children and adults with fragile X syndrome: An open‐label study

Artuela Çaku, David Pellerin, P Bouvier et al. · American Journal of Medical Genetics Part A · 2014 · 78 citations

Medicine, Neuroscience, Pharmacology +11

Long-term efficacy and safety of lerodalcibep in heterozygous familial hypercholesterolaemia: the LIBerate-HeFH trial

Frederick J. Raal, Nyda Fourie, Russell Scott et al. · European Heart Journal · 2023 · 67 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +17

Ser-Phosphorylation of PCSK9 (Proprotein Convertase Subtilisin-Kexin 9) by Fam20C (Family With Sequence Similarity 20, Member C) Kinase Enhances Its Ability to Degrade the LDLR (Low-Density Lipoprotein Receptor)

Ali Ben Djoudi Ouadda, Marie-Soleil Gauthier, Delia Susan‐Resiga et al. · Arteriosclerosis Thrombosis and Vascular Biology · 2019 · 55 citations · Full text

Life Sciences, Cell Biology, Molecular Biology +16

Lovastatin corrects ERK pathway hyperactivation in fragile X syndrome: potential of platelet’s signaling cascades as new outcome measures in clinical trials

David Pellerin, Artuela Çaku, Mathieu Fradet et al. · Biomarkers · 2016 · 50 citations

Medicine, Pharmacology, Pharmacotherapy +16